All In Biotech

Drug Trial Radar · NCT05662397

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

77

Actual

Start

Mar 15, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
HotSpot Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Dec 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

Conditions

  • Solid Tumor, Adult
  • Relapsed Cancer
  • Refractory Cancer

Interventions

  • HST-1011Drug

    HST-1011 given orally

  • CemiplimabBiological

    Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of escalating doses of single-agent HST-1011 in Part A1 or in combination with cemiplimab in Part B1.Time frame: 12 months
  2. To determine the Recommended Phase 2 Dose (RP2D) and schedule of HST-1011 monotherapy in Part A2 and in combination with cemiplimab in Part B2.Time frame: 12 months

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Einstein Comprehensive Cancer Center

    The Bronx, New York

  • Providence Cancer Institute of Oregon

    Portland, Oregon

  • Abramson Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh (UPMC), Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Ottawa

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • NEXT Oncology Barcelona IOB Hospital Quirónsalud

    Barcelona, Spain

  • Clínica Universidad de Navarra

    Madrid, Spain

  • NEXT Oncology Hospital Universitario Quirónsalud Madrid

    Madrid, Spain

  • Clínica Universidad de Navarra (Pamplona)

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.